within Pharmacolibrary.Drugs.ATC.S;

model S01BC05_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 5e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 120
  );

  annotation(Documentation(
    info ="<html><body><p>Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used for short-term management of moderate to severe pain, commonly following surgeries. It works by inhibiting cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins. Ketorolac is approved for use in many countries and is available in oral, intravenous, intramuscular, and ophthalmic formulations. The ATC code S01BC05 refers specifically to its ophthalmic (eye drop) formulation for the treatment of eye pain and inflammation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for ophthalmic (eye drop) administration are not well characterized in the literature; the following are estimates based on general ophthalmic NSAID pharmacokinetics.</p><h4>References</h4><ol><li><p>McCormack, PL (2011). Ketorolac 0.45% ophthalmic solution. <i>Drugs &amp; aging</i> 28(7) 583–589. DOI:<a href=&quot;https://doi.org/10.2165/11207450-000000000-00000&quot;>10.2165/11207450-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21721602/&quot;>https://pubmed.ncbi.nlm.nih.gov/21721602</a></p></li><li><p>Bertens, CJF, et al., &amp; Nuijts, RMMA (2021). Pharmacokinetics and efficacy of a ketorolac-loaded ocular coil in New Zealand white rabbits. <i>Drug delivery</i> 28(1) 400–407. DOI:<a href=&quot;https://doi.org/10.1080/10717544.2021.1883157&quot;>10.1080/10717544.2021.1883157</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33594935/&quot;>https://pubmed.ncbi.nlm.nih.gov/33594935</a></p></li><li><p>Attar, M, et al., &amp; Welty, D (2010). Ocular pharmacokinetics of 0.45% ketorolac tromethamine. <i>Clinical ophthalmology (Auckland, N.Z.)</i> 4 1403–1408. DOI:<a href=&quot;https://doi.org/10.2147/OPTH.S15146&quot;>10.2147/OPTH.S15146</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21179226/&quot;>https://pubmed.ncbi.nlm.nih.gov/21179226</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01BC05_1;
